Optimising SARS-CoV-2 vaccination schedules

The Lancet
Sep 04, 2021 Volume 398 Number 10303 p817-930, e12-e13


Optimising SARS-CoV-2 vaccination schedules
Cristobal Belda-Iniesta
… In summary, the question to be answered is whether the data published by Liu and colleagues, in combination with those previously published by Borobia and colleagues,3 are enough evidence to initiate the modification of vaccination schedules. Alternatively, large academic phase 3 clinical trials could explore the protection against severe disease, intensive care unit admission, and SARS-CoV-2 mortality using heterologous schedules, but the time and effort that this work would entail should be carefully balanced against the potential benefits.